Close menu

January 3rd, 2023 | 07:26 CET

New COVID outbreak in China: BioNTech, Cardiol Therapeutics, CureVac and Valneva shares in focus again in 2023

  • Biotechnology
  • Covid19
  • heartdisease
Photo credits:

The next COVID wave is rolling towards Europe. Representatives of the EU states therefore want to discuss a unified approach on Wednesday due to the latest development in China. The main issue is how to deal with entrants from China. A spokeswoman for the Federal Ministry of Health in Berlin said that the situation is being closely monitored and that the EU partners are also being consulted. At French airports, arrivals from China are already generally tested for the virus. Italy and Spain have also reacted with corresponding regulations. The German government sees no reason to do so so far. Is Germany too slow again, or is prudence the order of the day?

time to read: 5 minutes | Author: André Will-Laudien
ISIN: CARDIOL THERAPEUTICS | CA14161Y2006 , CUREVAC N.V. O.N. | NL0015436031 , VALNEVA SE EO -_15 | FR0004056851 , BIONTECH SE SPON. ADRS 1 | US09075V1026

Table of contents:

    BioNTech - Pipeline filled. Is the big leap coming in 2023?

    BioNTech is always keeping an eye on the pandemic, which has officially been declared over. The Mainz-based company, together with its partner Pfizer, had dominated the international vaccination scene from the very beginning and, together with Moderna, was able to achieve the greatest sales successes in the "vaccine" sector. More than 12 billion vaccine doses were produced worldwide, most of which were sold to the ordering governments. According to the latest available information, Germany is still awaiting orders for over 600 million vaccine doses. The German public does not know whether these will actually be delivered or whether they will be stockpiled at the cost of contractual penalties. However, the willingness to be vaccinated has decreased considerably. According to Statista, by November 13, 2022, some 63.5 million people in Germany, or 76.4% of the total population, had undergone a complete vaccination against the SARS-CoV-2 coronavirus. To date, however, only 12.8% have had a fourth vaccination; the personal attitudes of citizens have seemingly turned.

    BioNTech has announced several times that it will invest the approximately EUR 20 billion cash in other research areas. Oncology research is also on the list. After the great economic success with COVID-19, the Mainz-based company can therefore be expected to come up with one or more new developments in the new year. A clinical study on a possible malaria vaccine candidate was started before Christmas. After a low of EUR 111 in the middle of 2022, the share price stabilized again at EUR 143 at the end of the year but was still down 30% for the year. Analysts halved the 2023 sales estimate compared with 2022 to EUR 8.7 billion from EUR 16.5 billion, and the bottom line is expected to be around EUR 3.8 billion. With a market capitalization of around EUR 34 billion and a P/E ratio of 9, the share is no bargain, but the Mainz-based company, with its strong investor Strüngmann, should always be on the radar.

    Cardiol Therapeutics - Turning towards the heart

    Cardiol Therapeutics Inc (CRDL) is a biotechnology company specializing in the research and clinical development of innovative therapeutic methods for the treatment of cardiovascular diseases. The Company's promising product candidate, CardiolRx (cannabidiol), is a pharmaceutically manufactured oral solution formulation clinically developed for use in heart disease. Cannabidiol is known to inhibit activation of the inflammasome signaling pathway, which is known to play an important role in inflammation and fibrosis associated with myocarditis, pericarditis and heart failure.

    In December, the Company initiated a Phase II pilot study for the treatment of recurrent pericarditis. Commenting on this important milestone, Cardiol CEO David Elsley said, "Recurrent pericarditis is an inflammatory heart disease with symptoms such as stabbing chest pain, shortness of breath and fatigue that limit physical activity and quality of life for those affected. Data from patients enrolled in the study at our collaborating research centers will provide further information to support the use of CardiolRx as a novel therapy for this debilitating and often undertreated condition." The Company's Phase II pilot study is expected to enrol 25 patients at clinical centers in the United States that specialize in the treatment of pericarditis.

    Cardiol is also developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure, one of the leading causes of death and hospitalization in the developed world. In the US alone, the disease causes more than USD 30 billion in annual healthcare costs. Cardiol is making an important contribution to the research of this indication and its treatment.

    The CRDL share price made a 50% jump upwards in December 2022 on high turnover. Currently, the share price is consolidating at around CAD 0.72. With a market capitalization of only CAD 45.8 million, the stock is well below the cash balance of CAD 65.5 million from the last financial report on September 30, 2022. The Company has no significant debt, so the calculated enterprise value is minus CAD 20 million. After research expenditures beyond CAD 50 million, the share price should be trading well above the CAD 2.00 level. The analysts at Leede Jones Gable rate the stock a "Speculative Buy" with a price target of CAD 4.50. If the studies also run well, Cardiol could be a top pick for 2023.

    CureVac and Valneva - Why should shareholders still have these stocks on their list?

    Things have been quiet around vaccine researchers CureVac and Valneva. Both shares experienced a real Waterloo in 2022. Valneva had to give up 75%, and CureVac was down 83%. The problems of both companies were homemade. While Valneva took too much time to get an inactivated vaccine off the ground, at CureVac, it was the reduced efficacy of the vaccine developed that led to the short-term termination of research.
    As a result, CureVac posted a pre-tax loss of EUR120.4 million in the first 9 months of fiscal 2022 (2021: EUR 407.9 million). Revenues declined to EUR 55.7 million in the same period. Together with the British pharmaceutical company GlaxoSmithKline, however, CureVac continues to research flu vaccines. A total of four Phase 1 trials have been initiated for these. The new vaccine candidates are based on CureVac's second-generation mRNA scaffold and are currently being tested as booster vaccines. The trials are expected to deliver clinical data in the first quarter of 2023.

    French-Austrian Valneva has responded operationally very strongly to the COVID-EU setback. By downsizing its business units, annual savings of about EUR 12 million are now expected. 20 to 25% of the 750 employees worldwide are to be made redundant. In the first 9 months, Valneva more than tripled revenues to EUR 249.9 million (previous year: EUR 69.8 million). Below the line, the loss was reduced to around EUR 99 million, compared to EUR 228 million in the previous year. The Group reaffirmed its sales target of EUR 340 to 360 million for the full year. The forecast is based on the expectation of a sustained recovery in travel vaccines. In addition, further payments are expected for the delivery of the inactivated Corona vaccine.

    After the heavy losses in 2022, a technical recovery coupled with speculative buying related to the new Corona wave is likely to be possible for both stocks.

    Research efforts in vaccines and cardiovascular disease are extensive and costly. For the competing protagonists, good refinancing is necessary. Precisely this is available at BioNTech and Cardiol Therapeutics.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    André Will-Laudien

    Born in Munich, he first studied economics and graduated in business administration at the Ludwig-Maximilians-University in 1995. As he was involved with the stock market at a very early stage, he now has more than 30 years of experience in the capital markets.

    About the author

    Related comments:

    Commented by Fabian Lorenz on November 30th, 2023 | 07:10 CET

    Biotech Alert! Morphosys, Bayer, BioNTech and Defence Therapeutics

    • Biotechnology
    • Pharma

    Morphosys is not for the faint-hearted. After unclear study results, the stock gave up its annual gains within a few days. Analysts are also divided on what the future holds. On December 10, the study details will be released, hopefully shedding light on the situation. Bayer shareholders are currently seeing dark clouds. The stock plummeted from EUR 40 to EUR 30 in a short time. Is the dividend now at risk, or is the entire company in jeopardy? There is a slew of positive news for Defence Therapeutics. Can the stock break out of its sideways trend? A potential partner for the Canadians could be BioNTech. The German biotech favourite is working with full coffers on cancer vaccines. However, analysts remain cautious.


    Commented by Armin Schulz on November 29th, 2023 | 06:30 CET

    MorphoSys, Cardiol Therapeutics, Bayer - Where will the rebound start first?

    • Biotechnology
    • Pharma

    2023 was a challenging year for pharmaceutical and biotech companies. After the boom years of the Corona pandemic, many companies went into a tailspin. But not just vaccine manufacturers were hit; others were dragged down too. The markets are currently volatile. MorphoSys has seen a peak gain of 145% since the beginning of the year - but is currently only up 35%. Cardiol Therapeutics has also gained over 140% and has recently consolidated. The share is currently up 74% since the beginning of the year. Only Bayer's performance curve is pointing downwards. The share is currently worth 34% less than on January 2. We look at where the rebound will start first after the consolidations.


    Commented by Fabian Lorenz on November 23rd, 2023 | 07:40 CET

    Buy now? Morphosys, Siemens Energy and Desert Gold share

    • Mining
    • Gold
    • renewableenergies
    • Biotechnology

    What do renewable energies, biotech and gold have in common? Shares from these sectors have predominantly experienced significant losses in 2023. Morphosys, Siemens Energy and Desert Gold are examples of this. However, the underperformers in the current year are often among the top performers in the upcoming year. Can this apply to these three shares? In the case of Morphosys, the latest study data has been confusing, and the share has given back its gains of the year. Analysts are now expressing their views. Siemens Energy has lost over 30% of its value due to operational problems, and the price targets of the experts vary widely. Explorer Desert Gold has been quiet recently. Is it the calm before a price jump? In any case, the share is anything but expensive.